PT-141 (Bremelanotide)

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist. Originally derived from the tanning peptide Melanotan II during research by Competitive Technologies, it was discovered to have potent effects on sexual function independent of its melanogenic properties. In 2019, it was FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors that act peripherally on blood vessels, PT-141 works centrally through the nervous system, activating melanocortin receptors in the brain involved in sexual arousal and desire.

PT-141 acts primarily through central melanocortin receptor activation: **MC3R/MC4R Activation:** PT-141 is an agonist at melanocortin-3 and melanocortin-4 receptors, which are expressed in brain regions involved in sexual behavior, including the hypothalamus and limbic system. MC4R activation in particular appears critical for its sexual function effects. **Central Nervous System Action:** Unlike peripheral vasodilators, PT-141 activates central pathways that influence sexual desire and arousal. This mechanism affects the motivational and arousal components of sexual response rather than simply increasing blood flow. **Dopamine System Interaction:** The melanocortin system interacts with dopaminergic pathways involved in reward and motivation. PT-141's effects may partially involve modulation of dopamine signaling in relevant brain circuits. **Limited Melanogenic Effect:** While PT-141 retains some ability to activate MC1R (the tanning receptor), its cyclic structure and modifications result in reduced melanogenic activity compared to its precursor Melanotan II.